NEW ORLEANS — Hepatitis B is a global disease, and treatment remains
elusive, particularly in the pediatric population, according to a
presenter here at the 2012 AAP National Conference and Exhibition.
Judith A. O’Connor, MD, who is a
pediatric gastroenterologist at the University of Oklahoma Health
Sciences Center, said although treatment of HBV can be tricky in younger
patients, it is crucial because this illness has a profound effect on
their lives.
O’Connor said all of the treatment options for HBV have limitations.
Interferon’s assets include that these medications only require a
limited time frame for treatment, and they have the best antibody
responses, but, on the downside, they can be painful, they require
three-times-a-week dosing, and this is an expensive treatment, although
it is only for 1 year.
Read more..
No comments:
Post a Comment